Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
The patients were recruited from the Paediatric Outpatient Clinic, Division of Pulmonology, Allergy and Immunology, and followed at the Centre for Investigation in Paediatrics at State University of Campinas Hospital, Brazil.
The 37 patients (aged 7-19 years, 19 males) were randomized in two groups: magnesium (n=18, 300 mg/day) and placebo (n=19), during 2 months. Both patient groups received inhaled fluticasone (250 microgram twice a day) and salbutamol as needed. The primary outcome was bronchial reactivity evaluated with methacholine challenge test (PC20).
Oral magnesium supplementation helped to reduce bronchial reactivity to methacholine, to diminish their allergen-induced skin responses and to provide better symptom control in paediatric patients with moderate persistent asthma treated with inhaled fluticasone.